Bo Bjorkstrand
Overview
Explore the profile of Bo Bjorkstrand including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
668
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carlsten M, Jadersten M, Hellstrom A, Littmann K, Melen C, Junlen H, et al.
Exp Hematol Oncol
. 2019 Mar;
8:7.
PMID: 30923643
Background: Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality. Methods: All 433 lymphoma patients who underwent ASCT for lymphoma at Karolinska Huddinge 1994-2016...
2.
Blimark C, Turesson I, Genell A, Ahlberg L, Bjorkstrand B, Carlson K, et al.
Haematologica
. 2017 Dec;
103(3):506-513.
PMID: 29217784
Epidemiology and outcome of myeloma are mainly reported from large university centers and collaborative groups, and do not represent 'real-world' patients. The Swedish Myeloma Registry is a prospective population-based registry...
3.
Nahi H, Genell A, Walinder G, Uttervall K, Juliusson G, Karin F, et al.
Eur J Haematol
. 2017 May;
99(3):216-222.
PMID: 28544116
Solitary plasmacytoma (SP) and plasma cell leukemia (PCL) are uncommon (3-6%) types of plasma cell disease. The risk of progression to symptomatic multiple myeloma (MM) is probably important for the...
4.
Norin S, Bjorkstrand B, Rommel F, Timberg L, Andersson P, Haggstrom J, et al.
Leuk Res
. 2014 Dec;
39(1):33-7.
PMID: 25499233
There have been concerns about serious infusion-related adverse drug reactions (ADR) with rituximab in chronic lymphocytic leukemia (CLL). We therefore conducted an observational trial in which CLL patients planned for...
5.
Gahrton G, Iacobelli S, Bjorkstrand B, Hegenbart U, Gruber A, Greinix H, et al.
Blood
. 2013 Mar;
121(25):5055-63.
PMID: 23482933
Long-term follow-up of prospective studies comparing allogeneic transplantation to autologous transplantation in multiple myeloma is few and controversial. This is an update at a median follow-up of 96 months of...
6.
Bjorkstrand B, Iacobelli S, Hegenbart U, Gruber A, Greinix H, Volin L, et al.
J Clin Oncol
. 2011 Jul;
29(22):3016-22.
PMID: 21730266
Purpose: Results of allogeneic stem-cell transplantation (allo) in myeloma are controversial. In this trial autologous stem-cell transplantation (auto) followed by reduced-intensity conditioning matched sibling donor allo (auto-allo) was compared with...
7.
Morris C, Drake M, Apperley J, Iacobelli S, van Biezen A, Bjorkstrand B, et al.
Haematologica
. 2010 Oct;
95(12):2126-33.
PMID: 20971818
Background: As rare myelomas, i.e. the IgD, IgE, IgM and non-secretory forms, constitute only a small proportion of any study, relatively little is known about their prognosis in the era...
8.
Johnsen H, Bogsted M, Klausen T, Gimsing P, Schmitz A, Kjaersgaard E, et al.
Cytometry B Clin Cytom
. 2010 Jun;
78(5):338-47.
PMID: 20533391
Background And Aim: The clinical impact of multiparametric flow cytometry (MFC) in multiple myeloma (MM) is still unclear and under evaluation. Further progress relies on multiparametric profiling of the neoplastic...
9.
Waage A, Gimsing P, Fayers P, Abildgaard N, Ahlberg L, Bjorkstrand B, et al.
Blood
. 2010 May;
116(9):1405-12.
PMID: 20448107
In this double-blind, placebo-controlled study, 363 patients with untreated multiple myeloma were randomized to receive either melphalan-prednisone and thalidomide (MPT) or melphalan-prednisone and placebo (MP). The dose of melphalan was...
10.
Drake M, Iacobelli S, van Biezen A, Morris C, Apperley J, Niederwieser D, et al.
Haematologica
. 2010 May;
95(5):804-9.
PMID: 20442444
Background: Primary plasma cell leukemia is a rare disorder accounting for less than 5% of malignant plasma cell diseases. It has a poor prognosis compared to multiple myeloma, with a...